SCHEMBL31398950

SCHEMBL31398950

C#Cc1c(F)cc2c(nc(C(F)(F)F)n2C)c1OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31398959 0.83 CYP1A2 (0.32) —
SCHEMBL24463148 0.66 KDM4E (0.33) —
SCHEMBL17378584 0.63 CYP1A2 (0.40) —
SCHEMBL6950074 0.63 TLR8 (0.44) —
SCHEMBL15004570 0.62 PDE3B (0.40) —
SCHEMBL24463121 0.62 ACSS2 (0.39) —
SCHEMBL10187684 0.60 ACSS2 (0.52) —
SCHEMBL30038517 0.59 HSD11B1 (0.35) —
SCHEMBL28331893 0.59 CYP1A2 (0.40) —
SCHEMBL17417563 0.59 TAAR1 (0.45) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119176813-A Tricyclic heterocyclic compound with FGFR inhibition effect, pharmaceutical composition containing tricyclic heterocyclic compound and application of pharmaceutical composition 上海科恩泰生物医药科技有限公司 2024-12-24 — — CN disclosed
Send feedback